Catalent
CTLT
$55.78
Share price
-0.53%
Change (1 day)
22.78%
Change (1 year)
Categories
Catalent is an American pharmaceutical contract research and development company.
P/S ratio for Catalent (CTLT)
P/S ratio as of April 2024 (TTM): 2.47
According to Catalent's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.47335. At the end of 2023 the company had a P/S ratio of 1.98.
P/S ratio history for Catalent from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 1.98 | 16.31% |
| 2022 | 1.70 | -66.69% |
| 2021 | 5.11 | 3.35% |
| 2020 | 4.95 | 63.79% |
| 2019 | 3.02 | 65.48% |
| 2018 | 1.82 | -23.1% |
| 2017 | 2.37 | 33.8% |
| 2016 | 1.77 | 4.41% |
| 2015 | 1.70 | -9.11% |
| 2014 | 1.87 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | 2.70 | 9.24% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | 1.80 | -27.09% | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | 3.52 | 42.42% | 🇺🇸 USA |
 Intercept Pharmaceuticals
ICPT | 2.50 | 1.14% | 🇺🇸 USA |